久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

創生控股Trauson Holdings

　 創生控股有限公司（「創生控股」或「本公司」）及其附屬公司（統稱「本集團」或「集團」）是中國領先的骨科產品生產商，主要從事設計、制造及銷售多種創傷及脊柱骨科植入物，以及相關手術工具。集團正式始建于二零零二年十二月，由現任董事會主席兼首席執行官錢福卿先生創辦，是中國骨科市場的首批進入者之一。根據權威機構統計，創生控股以市場份額計算是中國骨科產品生產商中最大的創傷產品生產商及三大脊柱產品生產商之一。

　　截至二零一零年十二月三十一日，集團共有一百余種產品，并透過旗下品牌－「創生」及「奧斯邁」銷售。集團龐大的分銷網絡覆蓋全國三十個省市及自治區，有超過三千家醫院認可創生控股為骨科產品供貨商。

　　集團秉承「專業、專注、專心」的理念，自創建以來取得了迅速的增長。創生控股于二零一零年六月二十九日在其發展過程中取得了一個重要的里程碑，成功于香港聯合交易所有限公司（「香港聯交所」）主板上市（股份代號 325.HK ），成為為數不多的進入國際資本市場的中國骨科器械企業之一。
 

　　 創生控股旗下擁有兩家主要的全資控股企業：創生醫療器械（江蘇）有限公司（「創生江蘇」已于二零一一年三月二十三日更名為創生醫療器械（中國）有限公司）和常州奧斯邁醫療器械有限公司（「常州奧斯邁」）。于二零一零年十二月三十一日，本集團分別有三個廠區，總樓面面積達107,100平方米，集團的總資產達人民幣10.23億元。

　　集團擁有精良的制造加工設備及測量儀器，通過了中國醫療器械質量認證中心的ISO13485-2003質量體系認證，截止2010年底，公司獲得產品注冊證書100份，主要產品于2007年獲CE認證證書、2008年獲美國藥監局510（K）許可。「創生」商標被認定為中國馳名商標，是中國骨科領域唯一獲此殊榮的公司。

Trauson Holdings Company Limited (Trauson Holdings or the Company) and its subsidiaries (together as the Group) is a leading manufacturer of orthopaedic products in China. The Group was founded in December 2002 by the chairman and chief executive officer,Mr.Qian Fuqing,who is one of the forerunners in Chian''''''''''''''''s orthopaedic industry. According to an authoritative statistics, Trauson Holdings was the largest domestic producer of trauma products and one of the top three domestic producers of spine products in China by market share.
 

As at 31 December 2010, the Group had over 100 products marketed under its own brands, Trauson and Orthmed. The Groups extensive distribution network covered over 30 provinces and autonomous regions across China, with over 3,000 hospitals recognizing Trauson Holdings as their supplier of orthopaedic products.

Embracing the philosophy of professionalism, focus and concentration, the Group has experienced rapid growth since its inception. On 29 June 2010, Trauson Holdings reached an important milestone in its development when it was successfully listed on the Main Board of The Stock Exchange of Hong Kong Limited (the HKSE) (stock code: 325.HK), becoming one of the first China orthopaedic device companies to access the international capital market.

The Group has two principal and wholly-owned operating subsidiaries, Trauson (Jiangsu) Medical Instrument Company Limited (Trauson Jiangsu, which has been renamed as Trauson Medical Instrument (China) Company Limited with effect from 23 March 2011) and Changzhou Orthmed Medical Instrument Company Limited (Changzhou Orthmed). As at 31 December 2010, the Group had three production facilities with an aggregate floor area of 107,100 square metres, and total assets of approximately RMB1,023 million.

With the introduction of sophisticated manufacturing and processing equipments and measuring instruments, Trauson Holdings has also obtained the ISO13485-2003 certification of the China Quality Certification Center for Medical Devices. By the end of 2010, Trauson Holdings had received 100 registration certificates for its products. In addition, Trauson Holdings main product had attained CE marks and US FDA 510(K), in 2007 and 2008 respectively. TRAUSON is the only trademark that has been awarded the Well-known Chinese Brand in Chinas orthopaedic industry.